title: Quetiapine extended release for the treatment of bipolar disorder.
abstract: Management of bipolar disorder (BD) requires a complex combination of pharmacological and psychosocial interventions. Over recent decades the therapeutic arsenal for BD has expanded to include lithium, anticonvulsants and second-generation antipsychotics (SGAs). Immediate release (IR) quetiapine fumarate is a SGA approved in several countries for the treatment of patients with schizophrenia and BD or as an add-on treatment for major depressive disorders. Extended release (XR) quetiapine fumarate was developed more recently. There is interest in a once-daily formulation which may improve patient compliance but there may be some differences between quetiapine IR and XR in terms of safety and efficacy. This article provides an update of recent data on the efficacy and safety of quetiapine XR for the treatment of BD.
authors.affiliation: Centre Hospitalier Universitaire, Clermont-Ferrand, Adult Psychiatry B, Auvergne University, EA 7280, Clermont-Ferrand, France.
authors.forename: Ludovic
authors.initials: L
authors.lastname: Samalin
authors.forename: Aurore
authors.initials: A
authors.lastname: Tremey
authors.forename: Pierre-Michel
authors.initials: PM
authors.lastname: Llorca
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001714:Bipolar Disorder / Q000188:drug therapy*; D016208:Databases, Factual / Q000706:statistics & numerical data; D003987:Dibenzothiazepines / Q000008:administration & dosage* / Q000494:pharmacology; D016503:Drug Delivery Systems; D006801:Humans; D000069348:Quetiapine Fumarate
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate
keywords: bipolar disorder; depression; extended release; immediate release; mania; number need to harm; number need to treat; quetiapine; second-generation antipsychotic